The Post-Marketing Safety and Immunogenicity Research of Speeda® Rabies Vaccine for Human Use

Vaccination Adverse Event Clinical Trial

Official title:
Phase 4 Study of Speeda® Rabies Vaccine for Human Use

Status Completed

Clinical Trial Summary

The objective of this study was to achieve the post-marketing safety and immunogenicity research of Speeda® rabies vaccine for human use from Chengda Bio

Clinical Trial Description

The aim of the research is to compare the two immune procedures. The investigators plan to enroll 10500 participants signed the informed consent who separately inject by Zagreb or Essen procedure. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01821911
Study type	Interventional
Source	Beijing Center for Disease Control and Prevention
Contact
Status	Completed
Phase	Phase 4
Start date	July 2012
Completion date	December 2014

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01906593` - A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly	N/A
Completed	`NCT02133469` - PCV7 in the Prevention of Nasopharyngeal Carriage of Vaccine Serotype (VT) Streptococcus Pneumoniae	N/A
Completed	`NCT02133456` - A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3 Years and Older	N/A
Completed	`NCT01963338` - A Study to Assess the Acceptability and Usability of a New Device for Intradermal Vaccination	N/A